Different NT-proBNP circulating levels for different types of cardiac amyloidosis

Journal of Cardiovascular Medicine

Volumn 17, Issue 11, 2016, Pages 810-817

  Perfetto, Federico ^a   Bergesio, Franco ^a   Grifoni, Elisa ^a   Fabbri, Alessia ^a   Ciuti, Gabriele ^a   Frusconi, Sabrina ^a,b   Angelotti, Paola ^a   Spini, Valentina ^a   Cappelli, Francesco ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b Cytogenetics and Genetics Unit and   (Italy)

Author keywords

cardiac Biomarkers; Echocardiography; Immunoglobulin Lightchain Amyloidosis; Left Ventricular Mass Index; Mutated Transthyretin Amyloidosis; Wild Type Transthyretin Amyloidosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; IMMUNOGLOBULIN LIGHT CHAIN; PEPTIDE FRAGMENT; PREALBUMIN; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGED; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART AMYLOIDOSIS; HEART LEFT VENTRICLE MASS; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; TISSUE DOPPLER IMAGING; VERY ELDERLY; AMYLOIDOSIS; BLOOD; CARDIOMYOPATHY; CLASSIFICATION; DIAGNOSTIC IMAGING; DOPPLER ECHOCARDIOGRAPHY; GENETICS; HEART; HEART LEFT VENTRICLE FUNCTION; ITALY; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; AGED, 80 AND OVER; AMYLOIDOSIS; BIOMARKERS; CARDIOMYOPATHIES; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEART; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; ITALY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREALBUMIN; RETROSPECTIVE STUDIES; VENTRICULAR FUNCTION, LEFT;

EID: 85027944640     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0000000000000349     Document Type: Article

References (33)

1. Perfetto F, Cappelli F, Bergesio F, et al. Cardiac amyloidosis: The heart of the matter. Intern Emerg Med 2013; 8:191-203.
2. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998; 91:141-157.
3. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32:45-59.
4. Rapezzi C, Riva L, Quarta CC, et al. Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid 2008; 15:40-48.
5. Swiecicki PL, zhen DB, Mauermann ML, et al. Hereditary amyloidosis: A single-institution experience with 284 patients [abstract OP-53]. Presented at the XIVth International Symposium on Amyloidosis Amyloid 2013; 20:263-268.
6. Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: An Italian perspective. Eur Heart J 2013; 34:520-528.
7. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009; 120:1203-1212.
8. Dubrey SW, Cha K, Skinner M, et al. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 1997; 78:74-82.
9. Ng B, Connors LH, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure: A comparison with light chain-Associated amyloidosis. Arch Intern Med 2005; 165:1425-1429.
10. Connors LH, Prokaeva T, Lim A, et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 2009; 158:607-614.
11. Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004; 94:1008-1110.
12. Takemura G, Takatsu Y, Doyama K, et al. Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. J Am Coll Cardiol 1998; 31:754-765.
13. Suhr OB, Anan I, Backman C, et al. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? J Intern Med 2008; 263:294-301.
14. Palladini G, Saraiva MJ, Coelho T, et al. Differential effects on amyloidinduced myocardial dysfunction and N-Terminal-pro brain natriuretic peptide release of different amyloidogenic proteins. Eur Heart J 2004; 25 (Suppl 1):36.
15. Pinney JH, Whelan CJ, Petrie A, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Hear t Assoc 2013; 22:2.
16. Quarta CC, Solomon SD, Uraizee I, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation 2014; 6:1840-1849.
17. Benson MD, Breall J, Cummings OW, et al. Biochemical characterisation of amyloid by endomyocardial biopsy. Amyloid 2009; 16:9-14.
18. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112:2047-2060.
19. Westermark P, Sletten K, Johansson B, Cornwell GG. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 1990; 87:843-845.
20. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005; 46:1076-1084.
21. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours France, 18-22 April 2004. Am J Hematol 2005; 79:319-328.
22. Gertz MA, Merlini G. Definition of organ involvement and response to treatment in AL amyloidosis: An updated consensus opinion. Amyloid 2010; 17:48-49.
23. Palladini G, Perlini S, Merlini G. Imaging of systemic amyloidosis. In: Gertz MA, Rajkuma SV, editors. Amyloidosis: diagnosis and treatment. New York, USA: Humana Press; 2010. pp. 15-32.
24. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470.
25. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7:79-108.
26. Ganau A, Devereux RB, Roman MJ, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19:1550-1558.
27. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440-1463.
28. Lehrke S, Steen H, Kristen AV, et al. Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadoliniumenhanced cardiac magnetic resonance imaging in patients with amyloidosis. Amyloid 2009; 16:187-195.
29. Bernardi L, Passino C, Porta C, et al. Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension? Heart 2002; 88:615-621.
30. Perfetto F, Cappelli F, Bergesio F. Asymptomatic homozygous gene carrier in a family with Ile68Leu ATTR amyloidosis: A new endemic region in northern Tuscany? J Cardiovasc Med (Hagerstown) 2011; 12:450-451.
31. Cappelli F, Frusconi S, Bergesio F, et al. The Val142Ile transthyretin cardiac amyloidosis: not only an afro American pathogenic variant? An Italian experience. J Cardiovasc Med 2015; [Epub ahead of print].
32. Fontana M, Banypersad SM, Treibel TA, et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging 2014; 7:157-165.
33. Hutt DF, Quigley AM, Page J, et al. Utility and limitations of 3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging 2014; 15:1289-1298.